AnaptysBio (NASDAQ:ANAB) Insider Paul Lizzul Sells 3,650 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 3,650 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $44.71, for a total value of $163,191.50. Following the transaction, the insider owned 42,088 shares in the company, valued at $1,881,754.48. This represents a 7.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

AnaptysBio Trading Up 2.0%

ANAB opened at $44.67 on Friday. The stock’s 50 day simple moving average is $42.62 and its 200-day simple moving average is $31.46. The stock has a market cap of $1.24 billion, a PE ratio of -15.84 and a beta of 0.32. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $52.47.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. The company had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. Equities analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its board has approved a stock buyback program on Friday, November 21st that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. Assenagon Asset Management S.A. lifted its holdings in shares of AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after purchasing an additional 822,975 shares in the last quarter. Woodline Partners LP grew its holdings in shares of AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after buying an additional 305,950 shares in the last quarter. 683 Capital Management LLC grew its stake in shares of AnaptysBio by 155.6% during the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after acquiring an additional 304,373 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of AnaptysBio by 1,631.6% in the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after purchasing an additional 233,325 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of AnaptysBio by 145.6% in the third quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company’s stock worth $11,343,000 after purchasing an additional 219,648 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ANAB shares. Barclays dropped their target price on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Wells Fargo & Company increased their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Stifel Nicolaus dropped their target price on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Finally, UBS Group started coverage on AnaptysBio in a research report on Wednesday. They issued a “buy” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus price target of $60.40.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.